{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:54Z","timestamp":1786982754902,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T00:00:00Z","timestamp":1431561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s40261-015-0291-9","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T12:01:00Z","timestamp":1431518460000},"page":"375-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects"],"prefix":"10.1007","volume":"35","author":[{"given":"Hiroyuki","family":"Oshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wojtkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Kaibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Mujais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,14]]},"reference":[{"key":"291_CR1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-micro-090110-102824","volume":"65","author":"KC Carroll","year":"2011","unstructured":"Carroll KC, Bartlett JG. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol. 2011;65:501\u201321.","journal-title":"Annu Rev Microbiol"},{"key":"291_CR2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","volume":"359","author":"CP Kelly","year":"2008","unstructured":"Kelly CP, LaMont JT. Clostridium difficile\u2013more difficult than ever. N Engl J Med. 2008;359:1932\u201340.","journal-title":"N Engl J Med"},{"key":"291_CR3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1503\/cmaj.110543","volume":"184","author":"AJ Forster","year":"2012","unstructured":"Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with Clostridium difficile on length of stay in hospital. CMAJ. 2012;184:37\u201342.","journal-title":"CMAJ"},{"key":"291_CR4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/CMR.00082-09","volume":"23","author":"J Freeman","year":"2010","unstructured":"Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev. 2010;23:529\u201349.","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 1","key":"291_CR5","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1086\/521859","volume":"46","author":"RC Owens Jr","year":"2008","unstructured":"Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19\u201331.","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"291_CR6","first-page":"S28","volume":"27","author":"C Thomas","year":"2003","unstructured":"Thomas C, Riley TV. Restriction of third generation cephalosporin use reduces the incidence of Clostridium difficile-associated diarrhoea in hospitalised patients. Commun Dis Intell Q Rep. 2003;27(Suppl):S28\u201331.","journal-title":"Commun Dis Intell Q Rep."},{"key":"291_CR7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","volume":"69","author":"C Slimings","year":"2014","unstructured":"Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:881\u201391.","journal-title":"J Antimicrob Chemother"},{"key":"291_CR8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","volume":"41","author":"J P\u00e9pin","year":"2005","unstructured":"P\u00e9pin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254\u201360.","journal-title":"Clin Infect Dis"},{"key":"291_CR9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/595694","volume":"30","author":"AJ Kallen","year":"2009","unstructured":"Kallen AJ, Thompson A, Ristaino P, Chapman L, Nicholson A, Sim BT, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol. 2009;30:264\u201372.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"291_CR10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","volume":"353","author":"LC McDonald","year":"2005","unstructured":"McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433\u201341.","journal-title":"N Engl J Med"},{"key":"291_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.anaerobe.2013.10.004","volume":"25","author":"H Honda","year":"2014","unstructured":"Honda H, Yamazaki A, Sato Y, Dubberke ER. Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center. Anaerobe. 2014;25:5\u201310.","journal-title":"Anaerobe."},{"key":"291_CR12","doi-asserted-by":"crossref","first-page":"e005665","DOI":"10.1136\/bmjopen-2014-005665","volume":"4","author":"M Takahashi","year":"2014","unstructured":"Takahashi M, Mori N, Bito S. Multi-institution case-control and cohort study of risk factors for the development and mortality of Clostridium difficile infections in Japan. BMJ Open. 2014;4:e005665.","journal-title":"BMJ Open."},{"key":"291_CR13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"SH Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Society for Healthcare Epidemiology of America; Infectious Diseases Society of America, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431\u201355.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 2","key":"291_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","volume":"20","author":"SB Debast","year":"2014","unstructured":"Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1\u201326.","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"291_CR15","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/cid\/cis356","volume":"55","author":"DW Eyre","year":"2012","unstructured":"Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Infections in Oxfordshire Research Database. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012;55(Suppl 2):S77\u201387.","journal-title":"Clin Infect Dis"},{"key":"291_CR16","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","volume":"40","author":"J Pepin","year":"2005","unstructured":"Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591\u20137.","journal-title":"Clin Infect Dis."},{"key":"291_CR17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7164\/antibiotics.41.308","volume":"41","author":"B Cavalleri","year":"1988","unstructured":"Cavalleri B, Arnone A, Di Modugno E, Nasini G, Goldstein BP. Structure and biological activity of lipiarmycin B. J Antibiot (Tokyo). 1988;41:308\u201315.","journal-title":"J Antibiot (Tokyo)."},{"key":"291_CR18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkn269","volume":"62","author":"M Kurabachew","year":"2008","unstructured":"Kurabachew M, Lu SHJ, Krastel P, Schmitt EK, Suresh BL, Goh A, et al. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother. 2008;62:713\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"291_CR19","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/cid\/cis339","volume":"55","author":"EJC Goldstein","year":"2012","unstructured":"Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis. 2012;55(Suppl 2):S143\u20138.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"291_CR20","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","volume":"55","author":"TJ Louie","year":"2012","unstructured":"Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(Suppl 2):S132\u201342.","journal-title":"Clin Infect Dis"},{"key":"291_CR21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","volume":"60","author":"F Babakhani","year":"2011","unstructured":"Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol. 2011;60:1213\u20137.","journal-title":"J Med Microbiol"},{"issue":"Suppl 2","key":"291_CR22","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1093\/cid\/cis337","volume":"55","author":"P Sears","year":"2012","unstructured":"Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis. 2012;55(Suppl 2):S116\u201320.","journal-title":"Clin Infect Dis"},{"key":"291_CR23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, OPT-80-003 Clinical Study Group, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422\u201331.","journal-title":"N Engl J Med"},{"key":"291_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornley","year":"2012","unstructured":"Cornley OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, OPT-80-004 Clinical Study Group, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomized control trial. Lancet Infect Dis. 2012;12:281\u20139.","journal-title":"Lancet Infect Dis."},{"key":"291_CR25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","volume":"52","author":"YK Shue","year":"2008","unstructured":"Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother. 2008;52:1391\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"291_CR26","unstructured":"FDA label and approval history of Dificid, supplement number 004. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo . Accessed 14 Oct 2014."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0291-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0291-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:12:19Z","timestamp":1551186739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0291-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,14]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["291"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0291-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,14]]}}}